The General Pharmaceutical Council (GPhC) took regulatory action on almost three-quarters of the whistleblowing disclosures it received this year, a new report has revealed.
The GPhC’s annual whistleblowing disclosures report for 2026, published yesterday in conjunction with eight other health and social care professional regulators, said it had received “66 disclosures of information” between April 1, 2025 and March 31, 2026.
Read more: Exclusive: GPhC takes first enforcement action over POM ads
The figure represents a drop of almost 11% compared to last year, when the regulator received 74 disclosures overall.
Of the 66 whistleblowing disclosures received this year, 49 (74%) resulted in regulatory action being taken.
The GPhC said 47 of these were concluded by sharing information with its inspection team for follow-up action, while the remaining two cases were concluded with guidance.
It added that five concerns were signposted to another organisation, another five were closed with no further action and seven “remain under investigation”.
And it noted that the action it took “included a full investigation through our fitness-to-practise processes and follow‑up action through our inspection network”.
Read more: Exclusive: PSA appealed two GPhC decisions on sexual misconduct
The regulator also said that six disclosures from the previous year were closed with no further action, while one was concluded by sharing information with inspection colleagues and another was concluded with guidance.
Another concern from last year was concluded by the GPhC’s investigating committee issuing a warning, and a further two “remain under investigation”.
Read more: ‘Must do more’: Calls for Big Tech to tackle fake online pharmacies
It comes after the GPhC said Big Tech “must do more” to tackle illegal medicines sellers and stop people buying “counterfeit, unregulated and potentially dangerous medicines”.
And it follows C+D exclusively revealing that the Professional Standards Authority has successfully appealed two GPhC decisions on fitness-to-practise cases relating to sexual misconduct in recent years
